|
1
|
Zhai Y, Ni J, Jiang GW, et al: VEGI, a
novel cytokine of the tumor necrosis factor family, is an
angiogenesis inhibitor that suppresses the growth of colon
carcinomas in vivo. FASEB J. 13:181–189. 1999.PubMed/NCBI
|
|
2
|
Migone TS, Zhang J, Luo X, et al: TL1A is
a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell
costimulator. Immunity. 16:479–492. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang N, Sanders AJ, Ye L and Jiang WG:
Vascular endothelial growth inhibitor in human cancer (Review). Int
J Mol Med. 24:3–8. 2009.PubMed/NCBI
|
|
4
|
Muppidi JR, Tschopp J and Siegel RM: Life
and death decisions: secondary complexes and lipid rafts in TNF
receptor family signal transduction. Immunity. 21:461–465. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Locksley RM, Killeen N and Lenardo MJ: The
TNF and TNF receptor superfamilies: integrating mammalian biology.
Cell. 104:487–501. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kitson J, Raven T, Jiang YP, et al: A
death-domain-containing receptor that mediates apoptosis. Nature.
384:372–375. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chinnaiyan AM, O'Rourke K, Yu GL, et al:
Signal transduction by DR3, a death domain-containing receptor
related to TNFR-1 and CD95. Science. 274:990–992. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wen L, Zhuang L, Luo X and Wei P:
TL1A-induced NF-kappaB activation and c-IAP2 production prevent
DR3-mediated apoptosis in TF-1 cells. J Biol Chem. 278:39251–39258.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marsters SA, Sheridan JP, Donahue CJ, et
al: Apo-3, a new member of the tumor necrosis factor receptor
family, contains a death domain and activates apoptosis and
NF-kappa B. Curr Biol. 6:1669–1676. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Haridas V, Shrivastava A, Su J, et al:
VEGI, a new member of the TNF family activates nuclear factor-kappa
B and c-Jun N-terminal kinase and modulates cell growth. Oncogene.
18:6496–6504. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gout S, Morin C, Houle F and Huot J: Death
receptor-3, a new E-Selectin counter-receptor that confers
migration and survival advantages to colon carcinoma cells by
triggering p38 and ERK MAPK activation. Cancer Res. 66:9117–9124.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Porter PL: Global trends in breast cancer
incidence and mortality. Salud Publica Mex. 51(Suppl 2): 141–146.
2009. View Article : Google Scholar
|
|
13
|
Jiang WG, Watkins G, Fodstad O,
Douglas-Jones A, Mokbel K and Mansel RE: Differential expression of
the CCN family members Cyr61, CTGF and Nov in human breast cancer.
Endocr Relat Cancer. 11:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zuker M: Mfold web server for nucleic acid
folding and hybridization prediction. Nucleic Acids Res.
31:3406–3415. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang WG, Davies G and Fodstad O: Com-1/P8
in oestrogen regulated growth of breast cancer cells, the ER-beta
connection. Biochem Biophys Res Commun. 330:253–262. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sanders AJ, Parr C, Mason MD and Jiang WG:
Suppression of hepatocyte growth factor activator inhibitor-1 leads
to a more aggressive phenotype of prostate cancer cells in
vitro. Int J Mol Med. 20:613–619. 2007.PubMed/NCBI
|
|
17
|
Jiang WG, Martin TA, Lewis-Russell JM,
Douglas-Jones A, Ye L and Mansel RE: Eplin-alpha expression in
human breast cancer, the impact on cellular migration and clinical
outcome. Mol Cancer. 7:712008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang WG, Hiscox S, Hallett MB, Horrobin
DF, Mansel RE and Puntis MC: Regulation of the expression of
E-cadherin on human cancer cells by gamma-linolenic acid (GLA).
Cancer Res. 55:5043–5048. 1995.PubMed/NCBI
|
|
19
|
Jiang WG, Hiscox S, Hallett MB, Scott C,
Horrobin DF and Puntis MC: Inhibition of hepatocyte growth
factor-induced motility and in vitro invasion of human colon cancer
cells by gamma-linolenic acid. Br J Cancer. 71:744–752. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang WG, Hiscox SE, Parr C, et al:
Antagonistic effect of NK4, a novel hepatocyte growth factor
variant, on in vitro angiogenesis of human vascular endothelial
cells. Clin Cancer Res. 5:3695–3703. 1999.PubMed/NCBI
|
|
21
|
Parr C, Gan CH, Watkins G and Jiang WG:
Reduced vascular endothelial growth inhibitor (VEGI) expression is
associated with poor prognosis in breast cancer patients.
Angiogenesis. 9:73–81. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhai Y, Yu J, Iruela-Arispe L, et al:
Inhibition of angiogenesis and breast cancer xenograft tumor growth
by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer.
82:131–136. 1999. View Article : Google Scholar : PubMed/NCBI
|
